Takeda Pharmaceutical (TAK) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $58.39B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | JP | CEO | Julie So-Young Kim |
| IPO Date | 2010-01-05 | CAGR | 6.53% |
| Employees | 47,029 | Website | www.takeda.com |
| Div. Yield | 2.32% | Payout Ratio | 173% |
| Buy Back Yield | 59.37% | Total Yield | 61.69% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $12714.86B | P/E | 13.19 | Forward P/E | — | PEG | — |
| P/S | 2.95 | P/B | 1.78 | P/CF | 13.94 | P/FCF | 17.47 |
| Sales | $29.20B | Sales 1Y | 4.02% | Sales 3Y | 13.3% | Sales 5Y | 39.31% |
| EPS | $1.39 | EPS 1Y | 32.7% | EPS 3Y | -41.04% | EPS 5Y | -58.87% |
| Sales QoQ | 9.44% | EPS QoQ | -545.33% | Sales QoQ Avg | 2.72% | EPS QoQ Avg | -439.79% |
| Gross Margin | 62.15% | Operating Margin | 10.52% | Profit Margin | 3.91% | ROCE | 3.77% |
| ROA | 1% | ROE | 2% | Altman Z Score | 1.16 | Piotroski Score | 5 |
| Current Ratio | 1.14 | Quick Ratio | 0.62 | Cash Ratio | 0.17 | Op. CF Ratio | 0.01 |
| Debt/Equity | 0.65 | Debt/Assets | 0.32 | Lt Debt/Equity | 0.58 | Lt Debt/Cap. | 0.37 |
| Intrst Cov. | 1.55 | Inventory Turnover | 1.21 | Asset Turnover | 0.29 | Receivables Turnover | 4.83 |
| Enterprise Value | $12714.86B | P/E Ratio | 13.19 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 2.95 | P/B Ratio | 1.78 |
| P/CF Ratio | 13.94 | P/FCF Ratio | 17.47 |
| EPS | $1.39 | EPS Growth 1Y | 32.7% |
| EPS Growth 3Y | -41.04% | EPS Growth 5Y | -58.87% |
| Revenue Growth 1Y | 4.02% | Gross Margin | 0.62% |
| Operating Margin | 0.11% | Profit Margin | 0.04% |
| ROE | 0.02% | ROA | 0.01% |
| ROCE | 0.04% | Current Ratio | 1.14 |
| Quick Ratio | 0.62 | Cash Ratio | 0.17 |
| Debt/Equity | 0.65 | Interest Coverage | 1.55 |
| Altman Z Score | 1.16 | Piotroski Score | 5 |
Takeda Pharmaceutical (TAK) valuation & financials
Takeda Pharmaceutical (TAK) has a market capitalization of $58.39B and trades at a price-to-earnings ratio of 13.2. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Takeda Pharmaceutical's revenue grew +4.0% over the last year.
Takeda Pharmaceutical's next earnings report is scheduled for October 29, 2026 before market open; analysts estimate EPS of $0.14. Check the earnings calendar to see all companies reporting this week.
Takeda Pharmaceutical (TAK) — frequently asked questions
When does Takeda Pharmaceutical (TAK) report earnings next?
Takeda Pharmaceutical is expected to report earnings on October 29, 2026 before market open. Analysts estimate EPS of $0.14.
What is Takeda Pharmaceutical's market cap?
Takeda Pharmaceutical (TAK) has a market capitalization of $58.39B.
What is TAK's P/E ratio?
Takeda Pharmaceutical trades at a price-to-earnings ratio of 13.2, with trailing twelve-month EPS of $1.39.
How fast is Takeda Pharmaceutical growing?
Takeda Pharmaceutical's revenue grew +4.0% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)